Valiant Laboratories Ltd

Valiant Laboratories Ltd

Valiant Laboratories Ltd has published its standalone and consolidated audited financial results for the quarter and half year ended September 30, 2026, showing a total income from operations of ₹1,471,188 and a net profit of ₹108,332.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced its audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with the Board of Directors taking on record the Audit Report issued by Raman S. Shah & Co., Chartered Accountants.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced its audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with the Board of Directors approving the results and taking on record the Audit Report issued by Raman S. Shah & Co., Chartered Accountants.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has scheduled a Board Meeting on November 02, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter and half year ended September 30, 2026.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has enclosed a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming that all securities are held in dematerialized form and no requests for dematerialization, mutilation, or cancellation were received.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has closed its trading window for dealing in securities from October 1, 2026, until 48 hours after the declaration of Financial Results for the quarter and half year ended September 30, 2026, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the voting results of its 5th Annual General Meeting (AGM), where all 18 resolutions were passed with high voting percentages. The resolutions included the adoption of audited financial statements and the appointment of a director.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the voting results of its 5th Annual General Meeting (AGM), where all 18 resolutions were passed with high voting percentages. The company's audited standalone and consolidated financial statements for the financial year ended March 31, 2026, were also adopted.

Valiant Laboratories Ltd

Valiant Laboratories Ltd held its 5th Annual General Meeting (AGM) on September 28, 2026, through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The meeting was attended by 38 members, and the Board of Directors were formally introduced to the shareholders. The Managing Director presented the performance highlights of the Company, including improved business performance, successful completion of the Rights Issue, and commencement of commercial operations at the wholly owned subsidiary.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the completion of dispatch of its Annual Report for FY 2025-26 and Notice of 5th Annual General Meeting to be held on September 28, 2026, through Video Conferencing.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has received a credit rating of IND BBB/Stable/IND A2 for its bank loan facilities from India Ratings and Research (Ind-Ra).

Valiant Laboratories Ltd

Valiant Laboratories Ltd has dispatched letters to shareholders who had not registered their email addresses, informing them about the Annual Report for the Financial Year 2025-26 and the Notice of the 5th Annual General Meeting. The documents are available on the company's website and on stock exchange websites.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced its 5th Annual General Meeting (AGM) and Annual Report for FY 2025-26. The AGM will be held on September 28, 2026, through Video Conferencing / Other Audio Visual Means. The Annual Report is available on the company's website.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has released its Annual Report for FY 2025-26, which includes the Notice of the 5th Annual General Meeting (AGM) scheduled for September 28, 2026. The report highlights the company's expansion of manufacturing capacity, commercialization of Valiant Advanced Sciences, and investments in quality, operational excellence, and responsible business practices.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the 5th Annual General Meeting (AGM) through Video Conferencing/Other Audio Visual Means (VC/OAVM) on September 28, 2026, at 11:30 AM (IST). The meeting will be conducted in accordance with the Ministry of Corporate Affairs and SEBI circulars. Members will receive the notice and annual report through electronic mode, and the report will also be available on the company's website and stock exchanges' websites.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced its standalone and consolidated audited financial results for the quarter ended June 30, 2026, with total income from operations at ₹74,273.37 crore and net profit after tax at ₹9,478.8 crore.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has received a Monitoring Agency Report from India Ratings and Research Private Limited for the quarter ended June 30, 2026, stating that the proceeds from the Rights Issue have been utilized appropriately for the objects mentioned in the offer document.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the opening of a new corporate office, re-appointment of Managing Director and Independent Director, continuation of Non-Executive Non-Independent Director, and additional investment in a subsidiary.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the re-appointment of its Managing Director, Mr. Santosh Vora, and Independent Director, Mrs. Sonal Vira, for a further period. The company has also approved the continuation of directorship of Mr. Shantilal Vora, a Non-Executive Non-Independent Director. Additionally, the company has shifted its Registered Office and opened a new Corporate Office.

Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the re-appointment of its Managing Director, Mr. Santosh Vora, and Independent Director, Mrs. Sonal Vira, for a further period of five years. The company has also approved the continuation of directorship of Mr. Shantilal Vora as a Non-Executive Non-Independent Director. Additionally, the company has approved an investment of up to Rs. 60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited.